See the published version of this preprint at Cancer Cell International.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
TongZu Liu
Wuhan University Second Clinical Hospital: Wuhan University Zhongnan Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4669-5648
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Clear cell renal cell carcinoma (ccRCC) occupied most of renal cell carcinoma (RCC), which associated with poor prognosis. The purpose of this study is to screen novel and prognostic biomarkers for patients with ccRCC.
Methods and Results: Firstly, Gene Expression Omnibus database was used to collect microarray data for weighted gene co-expression network construction. Gene modules related to prognosis which interest us most were picked out. 90 hub genes were further chosen in the key modules, two of which including GNRH1 and LTB4R were screened and validated as immune-related prognostic biomarkers. Several methods including survival analysis, spearman correlation analysis, HPA, One-way ANOVA and ROC analysis were used for the validation of immune-related prognostic biomarkers. We further explored the relationship between immune-related prognostic biomarker expressions and immunocytes. Finally, gene set enrichment analysis (GSEA) demonstrated that the two immune-related prognostic biomarkers were significantly correlated with cell cycle.
Conclusions: Generally speaking, the present study has identified two novel prognostic biomarkers for patients with ccRCC, which showed strong correlation with prognosis of patients with ccRCC, could further be used as potential prognostic biomarkers in ccRCC.
Keywords
immune-related genes, clear cell renal cell carcinoma, prognostic biomarkers, immune infiltration, WGCNA
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
This is a list of supplementary files associated with this preprint. Click to download.
- Table1.xlsx
Table S1: GO biological processes of genes in brown module.
Loading...
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Cancer Cell International.
Version (no preprint)
Posted 07 Jun, 2021
Reviewer #2 agreed
On 07 Jun, 2021
Reviewer #1 agreed
On 07 Jun, 2021
Review #2 received
Received 07 Jun, 2021
Review #1 received
Received 07 Jun, 2021
Reviewers invited
Invitations sent on 07 Jun, 2021
Editor assigned
On 07 Jun, 2021
Submission checks complete
On 06 Jun, 2021
Editor invited
On 06 Jun, 2021
First submitted
On 06 Jun, 2021
Editorial decision: Minor revision
On 07 May, 2021
This version was not preprinted
Version 1
Posted 28 Apr, 2021
No community comments so far
Editorial decision: Major revision
On 06 May, 2021
Reviewer #4 agreed
On 04 May, 2021
Review #3 received
Received 03 May, 2021
Review #2 received
Received 03 May, 2021
Reviewer #3 agreed
On 02 May, 2021
Reviewer #2 agreed
On 30 Apr, 2021
Reviewers invited
Invitations sent on 25 Apr, 2021
Reviewer #1 agreed
On 25 Apr, 2021
Review #1 received
Received 25 Apr, 2021
Reviews received
Received 25 Apr, 2021
Editor invited
On 20 Apr, 2021
Editor assigned
On 19 Apr, 2021
Submission checks complete
On 19 Apr, 2021
First submitted
On 13 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
Learn more about our company.
See the published version of this preprint at Cancer Cell International.
This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Learn more about In Review
Research Article
TongZu Liu
Wuhan University Second Clinical Hospital: Wuhan University Zhongnan Hospital
Corresponding Author
ORCiD: https://orcid.org/0000-0003-4669-5648
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
Peer Review Timeline
CURRENT STATUS: Published
View the published article at Cancer Cell International.
Version (no preprint)
Posted 07 Jun, 2021
Reviewer #2 agreed
On 07 Jun, 2021
Reviewer #1 agreed
On 07 Jun, 2021
Review #2 received
Received 07 Jun, 2021
Review #1 received
Received 07 Jun, 2021
Reviewers invited
Invitations sent on 07 Jun, 2021
Editor assigned
On 07 Jun, 2021
Submission checks complete
On 06 Jun, 2021
Editor invited
On 06 Jun, 2021
First submitted
On 06 Jun, 2021
Editorial decision: Minor revision
On 07 May, 2021
This version was not preprinted
Version 1
Posted 28 Apr, 2021
No community comments so far
Editorial decision: Major revision
On 06 May, 2021
Reviewer #4 agreed
On 04 May, 2021
Review #3 received
Received 03 May, 2021
Review #2 received
Received 03 May, 2021
Reviewer #3 agreed
On 02 May, 2021
Reviewer #2 agreed
On 30 Apr, 2021
Reviewers invited
Invitations sent on 25 Apr, 2021
Reviewer #1 agreed
On 25 Apr, 2021
Review #1 received
Received 25 Apr, 2021
Reviews received
Received 25 Apr, 2021
Editor invited
On 20 Apr, 2021
Editor assigned
On 19 Apr, 2021
Submission checks complete
On 19 Apr, 2021
First submitted
On 13 Apr, 2021
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Cancer Biology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
View the published article at Cancer Cell International.
Background: Clear cell renal cell carcinoma (ccRCC) occupied most of renal cell carcinoma (RCC), which associated with poor prognosis. The purpose of this study is to screen novel and prognostic biomarkers for patients with ccRCC.
Methods and Results: Firstly, Gene Expression Omnibus database was used to collect microarray data for weighted gene co-expression network construction. Gene modules related to prognosis which interest us most were picked out. 90 hub genes were further chosen in the key modules, two of which including GNRH1 and LTB4R were screened and validated as immune-related prognostic biomarkers. Several methods including survival analysis, spearman correlation analysis, HPA, One-way ANOVA and ROC analysis were used for the validation of immune-related prognostic biomarkers. We further explored the relationship between immune-related prognostic biomarker expressions and immunocytes. Finally, gene set enrichment analysis (GSEA) demonstrated that the two immune-related prognostic biomarkers were significantly correlated with cell cycle.
Conclusions: Generally speaking, the present study has identified two novel prognostic biomarkers for patients with ccRCC, which showed strong correlation with prognosis of patients with ccRCC, could further be used as potential prognostic biomarkers in ccRCC.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15
This is a list of supplementary files associated with this preprint. Click to download.
- Table1.xlsx
Table S1: GO biological processes of genes in brown module.
Loading...